Venn Life Sciences Holdings PLC Directorate Change (2203L)
08 Janvier 2016 - 8:00AM
UK Regulatory
TIDMVENN
RNS Number : 2203L
Venn Life Sciences Holdings PLC
08 January 2016
8 January 2016
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Directorate Change
Venn Life Sciences (AIM: VENN), a growing Contract Research
Organisation (CRO) providing drug development, clinical trial
management and resourcing solutions to pharmaceutical,
biotechnology and medical device clients, announces that
Non-Executive Chairman David Evans, aged 55, has resigned his
position on the Board in line with his personal commitment to
reduce the number of Non-Executive Chairman roles currently
undertaken.
David remains a keen supporter and shareholder of Venn and will
work with the Board to find a suitable replacement and to
facilitate a smooth handover to his successor; a process which the
Company hopes to conclude by April 2016. In the interim period Tony
Richardson will act as executive Chairman.
Commenting, David Evans, said:
"I am pleased to have contributed to Venn's growth through its
Admission to the AIM market in 2012 and successful execution of a
pan-European acquisition strategy. The business is now clearly
demonstrating that it is well positioned to bid for and secure
larger scale projects and to offer clients a much wider range of
capabilities across numerous geographies. Shareholders in Venn, and
I include myself in this, will be delighted to see a business with
a growing client base, a strong forward order book and the
opportunity to secure high quality repeat business. I believe now
is a good time to seek a successor who can take on the Chairman's
role as Venn enters a new phase of growth."
Venn CEO, Tony Richardson said:
"On behalf of the Board I would like to thank David for his
contribution over the last 4 years. We have welcomed his support
and advice as we've grown the business and appreciate that his
experience has been invaluable for the successful execution of our
strategy."
Enquiries:
Venn Life Sciences Holdings www.vennlifesciences.com
Plc
Tony Richardson, Chief Executive Tel: +353 154 99 341
Officer
Jonathan Hartshorn, Chief Financial Tel: +353 153 93 269
Officer
Orla McGuinness, Marketing Tel: +353 153 93 269
Manager
Zeus Capital (Nominated Adviser
and Joint Broker)
Andrew Jones / Phil Walker
Dominic Wilson / Alex Davis Tel :+44(0)20 3829
5000
Hybridan LLP (Joint-Broker)
Claire Louise Noyce Tel: +44(0)20 3764
2341
Walbrook PR Ltd Tel: 020 7933 8787 or venn@walbrookpr.com
Lianne Cawthorne Mob: 07584 391 303
About Venn Life Sciences Limited: Venn Life Sciences is a
Contract Research Organisation providing drug development, clinical
trial management and resourcing solutions to pharmaceutical,
biotechnology and medical device organisations. With dedicated
operations in France, Germany, the Netherlands, the UK, Ireland and
Europe wide representation - Venn Life Sciences specialises in
rapid deployment and management of multisite projects, across all
phases. Venn Life Sciences also has an innovation division -
Innovenn - focused primarily on breakthrough development
opportunities in Skin Science.
For more information about the Company, please visit:
www.vennlifesciences.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOABCGDBRSGBGLR
(END) Dow Jones Newswires
January 08, 2016 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024